osimertinib,gefitinib
Astrazeneca
['detection', 'nsclc', 'apple trial', 'sclc', 'gefitinib']
the #oncoalerttoptweet #esmo22 day 3 tweet oncoalert colleague apple trial: in egfrm ansclc , detection of molecular pd w/o recist pd during gefitinib is feasible in up to 20% of pts, allowing early switch to osi with 18-mo pfs best, 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??